European Journal of Cancer, ISSN 0959-8049, 09/2018, Volume 101, pp. S21 - S21
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 01/2017, Volume 56, Issue 1, pp. 29 - 31
MYCOSIS-FUNGOIDES | EORTC | DERMATOLOGY | Lymphoma, T-Cell, Cutaneous - pathology | Skin Neoplasms - pathology | Young Adult | Lymphoma, T-Cell, Cutaneous - diagnosis | Humans | Skin Neoplasms - diagnosis | T-Lymphocytes - chemistry | Female | T cells | Skin | Lymphomas | Lymphocytes T | Lymphoma | T-cell lymphoma
Journal Article
Orphanet Journal of Rare Diseases, ISSN 1750-1172, 11/2014, Volume 9, Issue 1, p. 160
Background: Subcutaneous panniculitis-like T cell lymphomas represent a rare and difficult to diagnose entity of cutaneous T cell lymphomas. SPTL affects...
Subcutaneous panniculitis-like T-cell lymphoma | Th1-type | IDO-1 | Immunosuppressive tumor microenvironment | MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNITY | DIFFERENTIAL EXPRESSION | CHEMOKINES | INTERFERON-GAMMA | IDO | INFLAMMATION | CXCR3 | GENETICS & HEREDITY | TRYPTOPHAN DEGRADATION | TH1 | PROMOTES | Immunohistochemistry | Indoleamine-Pyrrole 2,3,-Dioxygenase - genetics | Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism | Oligonucleotide Array Sequence Analysis | Skin - metabolism | Humans | Middle Aged | Autoimmunity - genetics | Male | Lymphoma, T-Cell - metabolism | Panniculitis - genetics | Young Adult | Adult | Female | Cytokines - genetics | Real-Time Polymerase Chain Reaction | Cytokines - metabolism | Up-Regulation - genetics | Chemokines, CXC - genetics | Lymphoma, T-Cell - genetics | Chemokine CXCL9 - genetics | Chemokine CXCL9 - metabolism | Adolescent | Chemokines, CXC - metabolism | Immune Tolerance - genetics | Aged | Panniculitis - metabolism | Autoimmunity | Complications and side effects | Immunosuppression | Analysis | Genetic aspects | Non-Hodgkin's lymphomas | Research | Chemical properties | Gene expression | Health aspects | Risk factors | Genetic research
Subcutaneous panniculitis-like T-cell lymphoma | Th1-type | IDO-1 | Immunosuppressive tumor microenvironment | MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNITY | DIFFERENTIAL EXPRESSION | CHEMOKINES | INTERFERON-GAMMA | IDO | INFLAMMATION | CXCR3 | GENETICS & HEREDITY | TRYPTOPHAN DEGRADATION | TH1 | PROMOTES | Immunohistochemistry | Indoleamine-Pyrrole 2,3,-Dioxygenase - genetics | Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism | Oligonucleotide Array Sequence Analysis | Skin - metabolism | Humans | Middle Aged | Autoimmunity - genetics | Male | Lymphoma, T-Cell - metabolism | Panniculitis - genetics | Young Adult | Adult | Female | Cytokines - genetics | Real-Time Polymerase Chain Reaction | Cytokines - metabolism | Up-Regulation - genetics | Chemokines, CXC - genetics | Lymphoma, T-Cell - genetics | Chemokine CXCL9 - genetics | Chemokine CXCL9 - metabolism | Adolescent | Chemokines, CXC - metabolism | Immune Tolerance - genetics | Aged | Panniculitis - metabolism | Autoimmunity | Complications and side effects | Immunosuppression | Analysis | Genetic aspects | Non-Hodgkin's lymphomas | Research | Chemical properties | Gene expression | Health aspects | Risk factors | Genetic research
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 57 - 74
Abstract In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and...
Hematology, Oncology and Palliative Medicine | Chemotherapy | Total skin electron beam therapy | Immunotherapy | Skin-directed therapy | Mycosis fungoides | Retinoids | Sézary syndrome | Radiotherapy | Cutaneous T-cell lymphomas | Phototherapy | PEGYLATED LIPOSOMAL DOXORUBICIN | UV-B THERAPY | BONE-MARROW-TRANSPLANTATION | T-CELL LYMPHOMA | LOW-DOSE BEXAROTENE | SKIN ELECTRON-BEAM | PHASE-II TRIAL | ALPHA-2A PLUS PUVA | Sezary syndrome | ONCOLOGY | ORAL METHOXSALEN-PHOTOCHEMOTHERAPY | TOPICAL NITROGEN-MUSTARD | Skin Neoplasms - pathology | Immunotherapy - methods | Skin Neoplasms - therapy | Humans | Interferon-alpha - therapeutic use | Electrons - therapeutic use | Dermatologic Agents - therapeutic use | Consensus | Biological Factors - therapeutic use | Mycosis Fungoides - pathology | Phototherapy - methods | Retinoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mycosis Fungoides - therapy | Sezary Syndrome - therapy | Watchful Waiting | Combined Modality Therapy - methods | Histone Deacetylase Inhibitors - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Neoplasm Staging | Sezary Syndrome - pathology | Practice Guidelines as Topic | Mycoses | Care and treatment | Research | Oncology, Experimental | Cancer
Hematology, Oncology and Palliative Medicine | Chemotherapy | Total skin electron beam therapy | Immunotherapy | Skin-directed therapy | Mycosis fungoides | Retinoids | Sézary syndrome | Radiotherapy | Cutaneous T-cell lymphomas | Phototherapy | PEGYLATED LIPOSOMAL DOXORUBICIN | UV-B THERAPY | BONE-MARROW-TRANSPLANTATION | T-CELL LYMPHOMA | LOW-DOSE BEXAROTENE | SKIN ELECTRON-BEAM | PHASE-II TRIAL | ALPHA-2A PLUS PUVA | Sezary syndrome | ONCOLOGY | ORAL METHOXSALEN-PHOTOCHEMOTHERAPY | TOPICAL NITROGEN-MUSTARD | Skin Neoplasms - pathology | Immunotherapy - methods | Skin Neoplasms - therapy | Humans | Interferon-alpha - therapeutic use | Electrons - therapeutic use | Dermatologic Agents - therapeutic use | Consensus | Biological Factors - therapeutic use | Mycosis Fungoides - pathology | Phototherapy - methods | Retinoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mycosis Fungoides - therapy | Sezary Syndrome - therapy | Watchful Waiting | Combined Modality Therapy - methods | Histone Deacetylase Inhibitors - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Neoplasm Staging | Sezary Syndrome - pathology | Practice Guidelines as Topic | Mycoses | Care and treatment | Research | Oncology, Experimental | Cancer
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 2017, Volume 97, Issue 6, pp. 685 - 691
Staphylococcal enterotoxins have been shown to promote lymphoma-associated immune dysregulation. This study examined changes in the skin microbiome of...
Small-plaque parapsoriasis | Cutaneous microbes | Cutaneous microbial diversity | Skin microbiome | Large-plaque parapsoriasis | Cutaneous T-cell lymphoma | skin microbiome | cutaneous microbes | cutaneous microbial diversity | EN-PLAQUES | cutaneous T-cell lymphoma | large-plaque parapsoriasis | DIVERSITY | small-plaque parapsoriasis | PROGRESSION | CHILDREN | DERMATOLOGY | Skin - microbiology | Humans | Middle Aged | Male | Case-Control Studies | Bacteria - isolation & purification | Microbiota | Ribotyping | Parapsoriasis - diagnosis | Aged, 80 and over | Bacteria - classification | Parapsoriasis - microbiology | Adult | Female | Aged | cutaneousmicrobialdiversity | skinmicrobiome | cutaneousT-celllymphoma | large-plaqueparapsoriasis | cutaneousmicrobes | small-plaqueparapsoriasis
Small-plaque parapsoriasis | Cutaneous microbes | Cutaneous microbial diversity | Skin microbiome | Large-plaque parapsoriasis | Cutaneous T-cell lymphoma | skin microbiome | cutaneous microbes | cutaneous microbial diversity | EN-PLAQUES | cutaneous T-cell lymphoma | large-plaque parapsoriasis | DIVERSITY | small-plaque parapsoriasis | PROGRESSION | CHILDREN | DERMATOLOGY | Skin - microbiology | Humans | Middle Aged | Male | Case-Control Studies | Bacteria - isolation & purification | Microbiota | Ribotyping | Parapsoriasis - diagnosis | Aged, 80 and over | Bacteria - classification | Parapsoriasis - microbiology | Adult | Female | Aged | cutaneousmicrobialdiversity | skinmicrobiome | cutaneousT-celllymphoma | large-plaqueparapsoriasis | cutaneousmicrobes | small-plaqueparapsoriasis
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 72, Issue 2, pp. 352 - 353
Dermatology | DERMATOLOGY | Sezary Syndrome - immunology | Sezary Syndrome - mortality | Immunoglobulin E - immunology | Allergens - immunology | Antibody Specificity - immunology | Skin Neoplasms - immunology | Skin Neoplasms - mortality | Humans | Female | Male | Immunoglobulin E | Allergens | Allergy | Allergic reaction
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 06/2015, Volume 72, Issue 6, p. e179
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 2012, Volume 92, Issue 3, pp. 258 - 263
Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Literature on the efficacy, dosing...
Mycosis fungoides | Bexarotene | Sézary syndrome | Finland | Cutaneous T-cell lymphoma | ORAL BEXAROTENE | EFFICACY | cutaneous T-cell lymphoma | MYCOSIS-FUNGOIDES | CLASSIFICATION | RECEPTOR | SEZARY-SYNDROME | mycosis fungoides | DERMATOLOGY | bexarotene | TRIAL | Sezary syndrome | Hypothyroidism - chemically induced | Liver - enzymology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Tetrahydronaphthalenes - therapeutic use | Alanine Transaminase - blood | Lymphoma, T-Cell, Cutaneous - drug therapy | Liver - physiopathology | Tetrahydronaphthalenes - adverse effects | Aged, 80 and over | Adult | Anticarcinogenic Agents - adverse effects | Retrospective Studies | Neutropenia - chemically induced | Anticarcinogenic Agents - therapeutic use | Skin Neoplasms - pathology | Combined Modality Therapy | Lymphoma, T-Cell, Cutaneous - pathology | Hypertriglyceridemia - chemically induced | Aspartate Aminotransferases - blood | Aged | Hypercholesterolemia - chemically induced | Neoplasm Staging
Mycosis fungoides | Bexarotene | Sézary syndrome | Finland | Cutaneous T-cell lymphoma | ORAL BEXAROTENE | EFFICACY | cutaneous T-cell lymphoma | MYCOSIS-FUNGOIDES | CLASSIFICATION | RECEPTOR | SEZARY-SYNDROME | mycosis fungoides | DERMATOLOGY | bexarotene | TRIAL | Sezary syndrome | Hypothyroidism - chemically induced | Liver - enzymology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Tetrahydronaphthalenes - therapeutic use | Alanine Transaminase - blood | Lymphoma, T-Cell, Cutaneous - drug therapy | Liver - physiopathology | Tetrahydronaphthalenes - adverse effects | Aged, 80 and over | Adult | Anticarcinogenic Agents - adverse effects | Retrospective Studies | Neutropenia - chemically induced | Anticarcinogenic Agents - therapeutic use | Skin Neoplasms - pathology | Combined Modality Therapy | Lymphoma, T-Cell, Cutaneous - pathology | Hypertriglyceridemia - chemically induced | Aspartate Aminotransferases - blood | Aged | Hypercholesterolemia - chemically induced | Neoplasm Staging
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/1997, Volume 336, Issue 15, pp. 1041 - 1045
Photochemotherapy using oral methoxsalen (8-methoxypsoralen, or psoralen) and ultraviolet A radiation (PUVA) is a highly effective treatment for severe...
MEDICINE, GENERAL & INTERNAL | K PY MEDICINE, GENERAL & INTERNAL | 8-YEAR FOLLOW-UP | PHOTOCHEMOTHERAPY | PLUS ULTRAVIOLET | ORAL METHOXSALEN | TUMORS | A RADIATION | PATHOLOGISTS | Ultraviolet radiation | Psoriasis | Psoralens | Melanoma | Adverse and side effects | Drug therapy | Photochemotherapy | Risk factors | Side effects | Chemotherapy | Skin cancer
MEDICINE, GENERAL & INTERNAL | K PY MEDICINE, GENERAL & INTERNAL | 8-YEAR FOLLOW-UP | PHOTOCHEMOTHERAPY | PLUS ULTRAVIOLET | ORAL METHOXSALEN | TUMORS | A RADIATION | PATHOLOGISTS | Ultraviolet radiation | Psoriasis | Psoralens | Melanoma | Adverse and side effects | Drug therapy | Photochemotherapy | Risk factors | Side effects | Chemotherapy | Skin cancer
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 2017, Volume 97, Issue 6, pp. 735 - 738
Cutaneous T-cell lymphomas (CTCL), especially mycosis fungoides, can be considered as a state of longstanding low-grade systemic inflammation. Many studies...
Mycosis fungoides | Diabetes mellitus | Cutaneous T-cell lymphomas | Morbidity | cutaneous T-cell lymphomas | CANCERS | CARDIOVASCULAR-DISEASE | MYCOSIS-FUNGOIDES | RISK | CLASSIFICATION | diabetes mellitus | morbidity | SEZARY-SYNDROME | mycosis fungoides | DERMATOLOGY | Prevalence | Lymphoma, T-Cell, Cutaneous - diagnosis | Humans | Middle Aged | Male | Cause of Death | Diabetes Mellitus, Type 2 - epidemiology | Young Adult | Mycosis Fungoides - epidemiology | Time Factors | Lymphoma, T-Cell, Cutaneous - epidemiology | Skin Neoplasms - mortality | Skin Neoplasms - diagnosis | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Adult | Female | Mycosis Fungoides - mortality | Retrospective Studies | Cardiovascular Diseases - diagnosis | Mycosis Fungoides - diagnosis | Lymphoma, T-Cell, Cutaneous - mortality | Comorbidity | Hospitals, University | Skin Neoplasms - epidemiology | Lung Neoplasms - epidemiology | Aged | Lung Neoplasms - diagnosis | Finland - epidemiology | mycosisfungoides,cutaneousT-celllymphomas,morbidity,diabetesmellitus
Mycosis fungoides | Diabetes mellitus | Cutaneous T-cell lymphomas | Morbidity | cutaneous T-cell lymphomas | CANCERS | CARDIOVASCULAR-DISEASE | MYCOSIS-FUNGOIDES | RISK | CLASSIFICATION | diabetes mellitus | morbidity | SEZARY-SYNDROME | mycosis fungoides | DERMATOLOGY | Prevalence | Lymphoma, T-Cell, Cutaneous - diagnosis | Humans | Middle Aged | Male | Cause of Death | Diabetes Mellitus, Type 2 - epidemiology | Young Adult | Mycosis Fungoides - epidemiology | Time Factors | Lymphoma, T-Cell, Cutaneous - epidemiology | Skin Neoplasms - mortality | Skin Neoplasms - diagnosis | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Adult | Female | Mycosis Fungoides - mortality | Retrospective Studies | Cardiovascular Diseases - diagnosis | Mycosis Fungoides - diagnosis | Lymphoma, T-Cell, Cutaneous - mortality | Comorbidity | Hospitals, University | Skin Neoplasms - epidemiology | Lung Neoplasms - epidemiology | Aged | Lung Neoplasms - diagnosis | Finland - epidemiology | mycosisfungoides,cutaneousT-celllymphomas,morbidity,diabetesmellitus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 6, pp. e179 - e179
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 09/2016, Volume 96, Issue 6, pp. 816 - 817
MYCOSIS-FUNGOIDES | SINGLE-INSTITUTION | SEZARY-SYNDROME | SOCIETY | DERMATOLOGY | Lymphoma, T-Cell, Cutaneous - pathology | Skin Neoplasms - pathology | Skin Neoplasms - therapy | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Adult | Female | Lymphoma, T-Cell, Cutaneous - therapy | Male | Treatment Outcome
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2019, Volume 68, Issue 11, pp. 1904 - 1910
Abstract Background Three new parvoviruses of Protoparvovirus genus, bufavirus (BuV), tusavirus (TuV), and cutavirus (CuV), have recently been discovered in...
Journal Article
Postepy Dermatologii i Alergologii, ISSN 1642-395X, 06/2018, Volume 35, Issue 3, pp. 274 - 279
Introduction: Microbial infection and associated super antigens have been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL), and many patients...
Polymerase chain reaction | Late mycosis fungoides/Sézary syndrome stages | Chlamydophila pneumoniae | CHLAMYDIA-PNEUMONIAE | IFN-GAMMA PRODUCTION | MYCOSIS-FUNGOIDES | SEZARY-SYNDROME PATIENTS | PREVALENCE | DERMATOLOGY | INTERFERON-GAMMA | ALLERGY | late mycosis fungoides/Sezary syndrome stages | SMOOTH-MUSCLE-CELLS | INFECTION | ACTIVATING FACTOR | polymerase chain reaction | T-CELLS | Lymphomas | Fungal infections | Genetic recombination | Pathogenesis | Dermatitis | Deoxyribonucleic acid--DNA | Original Paper | late mycosis fungoides | Sézary syndrome stages
Polymerase chain reaction | Late mycosis fungoides/Sézary syndrome stages | Chlamydophila pneumoniae | CHLAMYDIA-PNEUMONIAE | IFN-GAMMA PRODUCTION | MYCOSIS-FUNGOIDES | SEZARY-SYNDROME PATIENTS | PREVALENCE | DERMATOLOGY | INTERFERON-GAMMA | ALLERGY | late mycosis fungoides/Sezary syndrome stages | SMOOTH-MUSCLE-CELLS | INFECTION | ACTIVATING FACTOR | polymerase chain reaction | T-CELLS | Lymphomas | Fungal infections | Genetic recombination | Pathogenesis | Dermatitis | Deoxyribonucleic acid--DNA | Original Paper | late mycosis fungoides | Sézary syndrome stages
Journal Article
Photodermatology, Photoimmunology & Photomedicine, ISSN 0905-4383, 09/2019, Volume 35, Issue 5, pp. 332 - 338
Background/Purpose Narrowband UVB phototherapy is a common treatment modality in psoriasis and atopic dermatitis, but evidence of its actual effect in clinical...
Scoring of Atopic Dermatitis | Patient‐Oriented SCORAD | Psoriasis Area and Severity Index | Dermatology Life Quality Index | Self‐Administrated PASI | SCORAD | EFFICACY | S3-GUIDELINES | Patient-Oriented SCORAD | UVB PHOTOTHERAPY | Self-Administrated PASI | DERMATOLOGY | PHOTOCHEMOTHERAPY | HELIOTHERAPY | INDEX | SEVERITY | Health care industry | Pruritus | Atopic dermatitis | Phototherapy | Medical care, Cost of | Index Medicus
Scoring of Atopic Dermatitis | Patient‐Oriented SCORAD | Psoriasis Area and Severity Index | Dermatology Life Quality Index | Self‐Administrated PASI | SCORAD | EFFICACY | S3-GUIDELINES | Patient-Oriented SCORAD | UVB PHOTOTHERAPY | Self-Administrated PASI | DERMATOLOGY | PHOTOCHEMOTHERAPY | HELIOTHERAPY | INDEX | SEVERITY | Health care industry | Pruritus | Atopic dermatitis | Phototherapy | Medical care, Cost of | Index Medicus
Journal Article
OncoImmunology, ISSN 2162-4011, 03/2017, Volume 6, Issue 3, p. e1273310
Indoleamine 2,3-deoxygenase 1 (IDO1) induces immune tolerance in the tumor microenvironment (TME) and is recognized as a potential therapeutic target. We...
tryptophan 2,3-dioxygenase | immunosuppressive microenvironment | kynurenine | indoleamine 2,3-dioxygenase 1 | Cutaneous T-cell lymphoma | INDOLEAMINE 2,3-DIOXYGENASE 1 | PROTEIN | PAPULOSIS | HODGKIN-LYMPHOMA | IMMUNOLOGY | 2,3-dioxygenase | microenvironment | indoleamine 2,3-dioxygenase1 | INHIBITION | ONCOLOGY | immunosuppressive | TUMORAL IMMUNE RESISTANCE | IDO2 | EXPRESSION | tryptophan
tryptophan 2,3-dioxygenase | immunosuppressive microenvironment | kynurenine | indoleamine 2,3-dioxygenase 1 | Cutaneous T-cell lymphoma | INDOLEAMINE 2,3-DIOXYGENASE 1 | PROTEIN | PAPULOSIS | HODGKIN-LYMPHOMA | IMMUNOLOGY | 2,3-dioxygenase | microenvironment | indoleamine 2,3-dioxygenase1 | INHIBITION | ONCOLOGY | immunosuppressive | TUMORAL IMMUNE RESISTANCE | IDO2 | EXPRESSION | tryptophan
Journal Article
Experimental Dermatology, ISSN 0906-6705, 05/2014, Volume 23, Issue 5, pp. 366 - 368
Sezary syndrome (SS) is an aggressive leukaemic variant of cutaneous T‐cell lymphoma. Recurrent chromosomal aberrations have been found in SS, but the whole...
APOPTOSIS | GENE | RESISTANCE | STAT4 | MYCOSIS-FUNGOIDES | T-CELL LYMPHOMA | LEUKEMIA | EXPRESSION | DELETION | DERMATOLOGY | Humans | Middle Aged | Repressor Proteins - genetics | Male | Gene Expression Profiling | Receptors, Cytoplasmic and Nuclear - genetics | Mutation, Missense | Sequence Analysis, DNA | DNA Copy Number Variations | Exome | T-Lymphocytes - cytology | Gene Deletion | Cell Cycle Proteins - genetics | Heterozygote | Receptor, EphA7 - genetics | Mutation | Nuclear Proteins - genetics | Sezary Syndrome - genetics | Apoptosis | Cohort Studies | Analysis | Leukemia | Genetic research | Genetic aspects | Non-Hodgkin's lymphomas | T cells | Gene expression
APOPTOSIS | GENE | RESISTANCE | STAT4 | MYCOSIS-FUNGOIDES | T-CELL LYMPHOMA | LEUKEMIA | EXPRESSION | DELETION | DERMATOLOGY | Humans | Middle Aged | Repressor Proteins - genetics | Male | Gene Expression Profiling | Receptors, Cytoplasmic and Nuclear - genetics | Mutation, Missense | Sequence Analysis, DNA | DNA Copy Number Variations | Exome | T-Lymphocytes - cytology | Gene Deletion | Cell Cycle Proteins - genetics | Heterozygote | Receptor, EphA7 - genetics | Mutation | Nuclear Proteins - genetics | Sezary Syndrome - genetics | Apoptosis | Cohort Studies | Analysis | Leukemia | Genetic research | Genetic aspects | Non-Hodgkin's lymphomas | T cells | Gene expression
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 03/2016, Volume 96, Issue 3, pp. 396 - 398
DERMATOLOGY | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Humans | Middle Aged | Neoplasm Recurrence, Local | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Remission Induction | Rituximab - administration & dosage | Young Adult | Time Factors | Antineoplastic Agents - adverse effects | Injections, Intralesional | Finland | Lymphoma, B-Cell - pathology | Adult | Female | Aged | Neoplasm Staging | Lymphoma, B-Cell - drug therapy | Rituximab - adverse effects
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 2015, Volume 95, Issue 5, pp. 593 - 595
Gestational pemphigoid, a rare autoimmune skin disease typically occurring during pregnancy, is caused by autoantibodies against collagen XVII. Clinically it...
Pemphigoid gestationis | Treatment | Cyclosporine | cyclosporine | treatment | PUSTULAR PSORIASIS | DIAGNOSIS | pemphigoid gestationis | LINKED-IMMUNOSORBENT-ASSAY | DERMATOSES | PREGNANCY | ANTIGEN | DERMATOLOGY | Glucocorticoids - administration & dosage | Humans | Sampling Studies | Dose-Response Relationship, Drug | Adult | Female | Drug Therapy, Combination | Glucocorticoids - adverse effects | Immunosuppressive Agents - administration & dosage | Severity of Illness Index | Pemphigoid Gestationis - immunology | Pemphigoid Gestationis - diagnosis | Drug Administration Schedule | Risk Assessment | Administration, Oral | Treatment Outcome | Pemphigoid Gestationis - drug therapy | Rare Diseases | Gestational Age | Pregnancy | Cyclosporine - adverse effects | Cyclosporine - administration & dosage | Finland | Immunosuppressive Agents - adverse effects | Pregnancy Outcome
Pemphigoid gestationis | Treatment | Cyclosporine | cyclosporine | treatment | PUSTULAR PSORIASIS | DIAGNOSIS | pemphigoid gestationis | LINKED-IMMUNOSORBENT-ASSAY | DERMATOSES | PREGNANCY | ANTIGEN | DERMATOLOGY | Glucocorticoids - administration & dosage | Humans | Sampling Studies | Dose-Response Relationship, Drug | Adult | Female | Drug Therapy, Combination | Glucocorticoids - adverse effects | Immunosuppressive Agents - administration & dosage | Severity of Illness Index | Pemphigoid Gestationis - immunology | Pemphigoid Gestationis - diagnosis | Drug Administration Schedule | Risk Assessment | Administration, Oral | Treatment Outcome | Pemphigoid Gestationis - drug therapy | Rare Diseases | Gestational Age | Pregnancy | Cyclosporine - adverse effects | Cyclosporine - administration & dosage | Finland | Immunosuppressive Agents - adverse effects | Pregnancy Outcome
Journal Article
Acta Dermato-Venereologica, ISSN 0001-5555, 2011, Volume 91, Issue 5, pp. 568 - 573
Bexarotene (Targretin (R)), was registered for the treatment of cutaneous T-cell lymphoma (CTCL) in 2002, and has been reported to induce a 45% overall...
Mycosis fungoides | Bexarotene | NAV3 | Sezary syndrome | Clinical response | Cutaneous T-cell lymphoma | ORAL BEXAROTENE | TRANSLOCATION | cutaneous T-cell lymphoma | TARGRETIN | SEZARY-SYNDROME | mycosis fungoides | DERMATOLOGY | bexarotene | clinical response | TRIAL | GENE | GENOMIC ABERRATIONS | SHOW | EXPRESSION | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Skin Neoplasms - drug therapy | Lymphoma, T-Cell, Cutaneous - immunology | Humans | Tetrahydronaphthalenes - therapeutic use | Antineoplastic Agents - therapeutic use | Lymphoma, T-Cell, Cutaneous - drug therapy | Lymphoma, T-Cell, Cutaneous - genetics | Patient Selection | Tetraploidy | Time Factors | Gene Deletion | Precision Medicine | Skin Neoplasms - pathology | Pharmacogenetics | Membrane Proteins - genetics | Cells, Cultured | In Situ Hybridization, Fluorescence | Treatment Outcome | Gene Dosage | Nerve Tissue Proteins - genetics | Remission Induction | Skin Neoplasms - genetics | Finland | Biomarkers, Tumor - genetics | Chromosomes, Human, Pair 12
Mycosis fungoides | Bexarotene | NAV3 | Sezary syndrome | Clinical response | Cutaneous T-cell lymphoma | ORAL BEXAROTENE | TRANSLOCATION | cutaneous T-cell lymphoma | TARGRETIN | SEZARY-SYNDROME | mycosis fungoides | DERMATOLOGY | bexarotene | clinical response | TRIAL | GENE | GENOMIC ABERRATIONS | SHOW | EXPRESSION | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Skin Neoplasms - drug therapy | Lymphoma, T-Cell, Cutaneous - immunology | Humans | Tetrahydronaphthalenes - therapeutic use | Antineoplastic Agents - therapeutic use | Lymphoma, T-Cell, Cutaneous - drug therapy | Lymphoma, T-Cell, Cutaneous - genetics | Patient Selection | Tetraploidy | Time Factors | Gene Deletion | Precision Medicine | Skin Neoplasms - pathology | Pharmacogenetics | Membrane Proteins - genetics | Cells, Cultured | In Situ Hybridization, Fluorescence | Treatment Outcome | Gene Dosage | Nerve Tissue Proteins - genetics | Remission Induction | Skin Neoplasms - genetics | Finland | Biomarkers, Tumor - genetics | Chromosomes, Human, Pair 12
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.